FDA panel backs Vanda's circadian rhythm drug

November 14, 2013 8:47 PM

7 0

FDA panel backs Vanda's circadian rhythm drug

(Reuters) - An advisory panel to the Food and Drug Administration said on Thursday that an experimental drug designed to help regulate the internal body clocks of blind patients appears safe and effective.

The drug, tasimelteon, is designed to treat Non-24-Hour Sleep-Wake Disorder, or Non-24, a condition that is most commonly found in the totally blind and can cause disrupted nighttime sleep patterns and excessive daytime sleepiness.

Read more

To category page

Loading...